Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis

NCT ID NCT07058298

Recruiting now Disease control Sponsor: Daishi Tian Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early study tests a new treatment called GC012F, made from a patient's own immune cells (CAR-T cells), for people with refractory generalized myasthenia gravis that hasn't responded to standard therapies. Six participants will receive a single infusion of these modified cells after a short chemotherapy prep. The main goal is to check safety and tolerability, while also looking for signs of improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC012F injection (CAR-T cells)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-control myasthenia gravis.
What could go wrong: This is a very early, small trial with only 6 people, so results may not apply widely. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS (GMG)

Contacts and locations

Locations

Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.